Navigation Links
Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY

the 4 mg oral dose of GLP-1 was 300 pMol/L.

In the PYY study, the drug was given orally to six healthy male subjects in a six way cross-over design. The treatment arms consisted of oral doses (0.25, 0.5, 1.0, 2.0 and 4.0 mg) of PYY with Emisphere's delivery agent administered as a single tablet versus placebo. The Cmax value of PYY for the 4 mg oral dose had a plasma concentration of 629 pg/ml. In addition, there was a reduction of Ghrelin in all groups administered PYY with the largest percent reduction in Ghrelin levels observed in the 4 mg PYY dose.

"This study showed for the first time that GLP-1 was active with regard to stimulation of insulin releases in humans after oral administration. In the subjects receiving the highest doses of oral GLP-1, we observed nausea effects similar to those seen when the subjects received high levels of injectable GLP-1. The biodynamic results on insulin release and blood concentrations indicate that oral GLP-1 could be an effective treatment in diabetes. The PYY results in combination with the GLP results could mean that oral PYY and oral GLP-1 could also be an effective treatment for other diseases such as obesity. We will seek to publish these results," said Dr. Christoph Beglinger of the University Hospital in Basel.

"We are very pleased to be working on the oral delivery of GLP-1 and PYY with a leading academic researcher such as Dr. Beglinger in the field of gastroenterology. The compounds GLP-1 and PYY are gastrointestinally produced hormones and GLP-1 is already an important compound in the treatment of diabetes as an injectable agent. Non-oral forms of these compounds are being explored in the treatment of obesity. We are looking forward in 2007 to initiating and completing a proof-of-concept efficacy study on the reduction of food intake using our oral incretin products with Dr. Beglinger," said Lewis H. Bender, President and CEO of Emisphere Technologies, Inc.

About GLP-1

Glucagon-l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/13/2008)... from Multiple Cancer Populations Facilitates ..., Mich., Oct. 13 /- Rubicon Genomics,...rick to amplify DNA samples for The,Cancer Atlas G...amplify and standardize total genomic,DNA from 3,0...The Rubicon,GenomePlex(TM) Whole Genome Amplificat...
(Date:10/12/2008)...lone and in Combination with Chemotherapy, FREMON...icals, Inc., a,development-stage pharmaceutical co...rence (RNAi)-based therapeutics, today announced t...on efficacy of siRNA targeting,its proprietary tar...) in,the edition dated October 1, 2008. The paper,...
(Date:10/12/2008)...NGTON, Oct. 12 /- Boston,Sc... results from an analysis,of nearly 7,500 patients...re designed to confirm the performance of the TAXU...t System in real-world practice. The,two-year pool... clinical,restenosis in patients with diabetes as ...
(Date:10/10/2008)...t. 10 /- Diplomat Specialty,Pharmacy ...d Diplomat,Specialty Pharmacy to be one of only th...l Therapy Optimization Study for Multiple Sclerosi...dy, is to examine the benefits of a,specialty phar...erence and,patient outcomes. Targeted patient outc...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 1Allscripts to Announce First Quarter 2008 Results on April 30 17431 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 1Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 2Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 4DURECT to Participate in Morgan Stanley Global Healthcare Conference 17424 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 2
... 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics...ase III multi- center clinical studies of ferumoxy... will be presented during,the National Kidney Foun...place April 10th through 14th in Orlando, Florida....be presented on,Wednesday, April 11, 2007 at appro...
...wed Complete Response or Reduction of,Lesion Size ... 05, 2007 /PRNewswire-FirstCall/ - Nventa,Biopharm...ation of,positive results from a clinical trial ex...spE7, an investigational therapeutic,vaccine for h...en,with the highest grade of cervical dysplasia (C...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6
(Date:10/13/2008)... AtlantaJobs.com and numerous newspaper affil...tlantaJobs.com . AtlantaJobs.com is the newest on...yers and jobseekers in the metro Atlanta area. , ...r 13, 2008 -- AtlantaJobs.com and numerous newsp... of AtlantaJobs.com is the newest online job boa...
(Date:10/12/2008)... /PRNewswire-USNewswire/ -- Several of Chicago,s,p...n an evening of sampling,and tasting on Monday, No...Chefs Auction. Celebrity Chef and March of Dimes s...Hell,s Kitchen (season 3) will also be in,attendan...-rich recipe for,women considering becoming pregna...
(Date:10/11/2008)...n online survey for World Arthritis Day (WAD), com...cess to psychological support and self-management ...m cope more effectively with their condition and a...onals, people with rheumatic disease and their car...portance of integrating psychological support into...
(Date:10/11/2008)...t International Transcends Cultural Divides, JOHA...uth African and,international audiences welcome Bi...ectrifying gathering, which for the first time is ...: http://www.newscom.com/cgi-bin/prnh/20081011/CL...cked off with performances by,South Africa,s own m...
Breaking Medicine News(10 mins):Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:Sample Signature Dishes of Chicago's Finest Chefs at the March of Dimes Chicago Signature Chefs Auction on Monday, November 10, 2008 2Health News:Call for new standards of care in arthritis/rheumatism 2Health News:Bishop T.D. Jakes Electrifies South Africa 2
...ts have developed a new minimally invasive method ... trials on individuals with prostate cancer soon ....le electroporation (IRE) is a result of the effort...r Rafael V. Davalos and University of California b...
...anners with standard commercial software designed ...ing coronary artery disease in as many as 40 perce..., professor in the Division of Cardiology at The U...ouston, said he discovered the abnormalities upon ...
..., a nanotechnology development company that is dev...lmonella announced today an update regarding its p...e Company stated that although it had received mul...d testing from its contract manufacturer, due to i...
...ing centre was Friday forced to call in police whe...ed overnight, demanded to be let in for the launch... that by Friday morning as many as two thousand pe...'s upmarket Landmark centre to buy the creation of...
Other Medicine News:Health News:Scientists Destroy Cancer Cells Using Electric Pulses 2Health News:Inaccuracies in Cardiac PET-CT Scanning 2Health News:Inaccuracies in Cardiac PET-CT Scanning 3Health News:NanoSensors Provides Update on Its Biosensor to Detect E.coli and Salmonella 2Health News:Designer Bag Launch Causes Shopping Chaos in Hong Kong 2
Substrate Plasma for Factor XII Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XII.
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of Tissue Plasminogen Activator Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests.
Medicine Products: